Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Kuala Lumpur Kepong (KLK) is a prominent Malaysian multinational conglomerate with a significant presence in the life sciences sector through its oleochemical division, KLK Oleo. The company specializes in the production of pharmaceutical-grade excipients and high-purity phytonutrients, notably through its subsidiary Davos Life Science. KLK is a global leader in the extraction of tocotrienols, a potent form of Vitamin E, which are marketed for nutraceutical and cosmeceutical applications. Their research and development efforts focus on the therapeutic potential of tocotrienols in treating metabolic diseases, cardiovascular health, and certain types of cancer. Additionally, KLK provides a wide range of bio-based specialty chemicals used as ingredients in the global pharmaceutical and personal care industries. The company's integrated business model spans from sustainable plantations to advanced downstream processing, ensuring high-quality standards for its health-related products.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Kuala Lumpur Kepong.